Menu
Menu
Fortis Healthcare has received CCI approval to acquire an additional 31.52% stake in Agilus Diagnostics, increasing its ownership to 89.2%. This strategic move aims to enhance integrated healthcare services, improve diagnostic capabilities, and ultimately benefit patient care. Explore the details and implications of this significant acquisition in the healthcare landscape.
Alembic Pharmaceuticals has achieved a major milestone with the FDA approval of its Alcaftadine Ophthalmic Solution, designed to relieve itchy eyes caused by common allergens. This new product positions Alembic to strengthen its presence in the ophthalmic market, alongside a solid financial performance that highlights the company's growth potential. Explore the implications of this approval and what it means for allergy sufferers and the pharmaceutical industry.
Shilpa Medicare's shares surged following the company's announcement of receiving a Certificate of Suitability (CEP) from the EDQM for Desmopressin, a key active pharmaceutical ingredient. This approval not only highlights Shilpa's commitment to quality and innovation but also positions it for future growth in the pharmaceutical market. Explore the implications of this milestone and its potential impact on patients and investors.
Lupin Ltd has announced a strategic partnership with Takeda to commercialize Vonoprazan, a novel gastrointestinal drug, in the Indian market. Marketed as Lupivon, this innovative treatment aims to enhance options for patients suffering from gastrointestinal disorders like GERD. Explore the implications of this collaboration and what it means for the future of gastrointestinal care in India.
Zydus Lifesciences has achieved a major milestone with USFDA approval for Amantadine extended-release capsules, aimed at treating dyskinesia in Parkinson’s disease patients. The company has also received tentative approval for Gocovri capsules, promising more affordable treatment options. Discover how these approvals could enhance access to essential Parkinson's disease therapies.
Zydus Lifesciences has achieved a significant breakthrough with regulatory approval from Mexico for Bhava, a cutting-edge biosimilar targeting multiple cancers. This milestone underscores Zydus Lifesciences' commitment to advancing oncology treatments globally, promising new hope for patients and healthcare providers alike.
In a groundbreaking development, Glenmark Pharmaceuticals has secured USFDA approval to market generic Topiramate Capsules, a pivotal medication for managing seizures and epilepsy. This approval underscores Glenmark's commitment to expanding healthcare access through affordable alternatives, while maintaining therapeutic equivalence to the branded version. Explore how this milestone enhances treatment options and reshapes the pharmaceutical landscape.
Explore Alembic Pharma's latest breakthrough: the USFDA approval of its Generic Bromfenac Ophthalmic Solution. This milestone not only enhances patient access to affordable postoperative care but also underscores Alembic's commitment to innovation in the pharmaceutical industry. Learn how this approval aligns with healthcare cost-efficiency efforts and supports quality treatment standards.
In a groundbreaking move aimed at enhancing accessibility and convenience in healthcare, Star Health Insurance has launched Home Health Care services across more than 50 cities in India. This initiative brings comprehensive medical care directly to individuals' doorsteps, facilitated by partnerships with trusted providers like Care24, Portea, CallHealth, and Athulya Homecare.
In a significant development, Zydus Lifesciences has achieved tentative approval from the FDA for its Azilsartan Medoxomil tablets, marking a pivotal step in expanding treatment options for hypertension. Learn more about how this milestone underscores Zydus Lifesciences' dedication to delivering quality healthcare solutions.